|
|
Blood, 1 October 2004, Vol. 104, No. 7, pp. 1931-1939.
Prepublished online as a Blood First Edition Paper on May 27, 2004; DOI 10.1182/blood-2004-01-0246.
 Previous Article | Table of Contents | Next Article 
REVIEW ARTICLES
Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders
Animesh Pardanani, and
Ayalew Tefferi
From the Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN.
Imatinib mesylate is a small molecule drug that in vitro inhibits the Abelson (Abl), Arg (abl-related gene), stem cell factor receptor (Kit), and platelet-derived growth factor receptor A and B (PDGFRA and PDGFRB) tyrosine kinases. The drug has acquired therapeutic relevance because of similar inhibitory activity against certain activating mutations of these molecular targets. The archetypical disease in this regard is chronic myeloid leukemia, where abl is constitutively activated by fusion with the bcr gene (bcr/abl). Similarly, the drug has now been shown to display equally impressive therapeutic activity in eosinophilia-associated chronic myeloproliferative disorders that are characterized by activating mutations of either the PDGFRB or the PDGFRA gene. The former usually results from translocations involving chromosome 5q31-33, and the latter usually results from an interstitial deletion involving chromosome 4q12 (FIP1L1-PDGFRA). In contrast, imatinib is ineffective, in vitro and in vivo, against the mastocytosis-associated c-kit D816V mutation. However, wild-type and other c-kit mutations might be vulnerable to the drug, as has been the case in gastrointestinal stomal cell tumors. Imatinib is considered investigational for the treatment of hematologic malignancies without a defined molecular drug target, such as polycythemia vera, myelofibrosis with myeloid metaplasia, and acute myeloid leukemia.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Haroche, Z. Amoura, F. Charlotte, J. Salvatierra, B. Wechsler, C. Graux, N. Brousse, and J.-C. Piette
Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis
Blood,
June 1, 2008;
111(11):
5413 - 5415.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. P. Piccaluga, C. Agostinelli, A. Califano, A. Carbone, L. Fantoni, S. Ferrari, A. Gazzola, A. Gloghini, S. Righi, M. Rossi, et al.
Gene Expression Analysis of Angioimmunoblastic Lymphoma Indicates Derivation from T Follicular Helper Cells and Vascular Endothelial Growth Factor Deregulation
Cancer Res.,
November 15, 2007;
67(22):
10703 - 10710.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. V. Gleixner, M. Mayerhofer, K. Sonneck, A. Gruze, P. Samorapoompichit, C. Baumgartner, F. Y. Lee, K. J. Aichberger, P. W. Manley, D. Fabbro, et al.
Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT
Haematologica,
November 1, 2007;
92(11):
1451 - 1459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Baccarani, D. Cilloni, M. Rondoni, E. Ottaviani, F. Messa, S. Merante, M. Tiribelli, F. Buccisano, N. Testoni, E. Gottardi, et al.
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR{alpha}-positive hypereosinophilic syndrome. Results of a multicenter prospective study
Haematologica,
September 1, 2007;
92(9):
1173 - 1179.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Huang, A. Wallqvist, and D. G. Covell
Targeting changes in cancer: assessing pathway stability by comparing pathway gene expression coherence levels in tumor and normal tissues.
Mol. Cancer Ther.,
September 1, 2006;
5(9):
2417 - 2427.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Guo, P. A. Marcotte, J. O. McCall, Y. Dai, L. J. Pease, M. R. Michaelides, S. K. Davidsen, and K. B. Glaser
Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors.
Mol. Cancer Ther.,
April 1, 2006;
5(4):
1007 - 1013.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. V. Gleixner, M. Mayerhofer, K. J. Aichberger, S. Derdak, K. Sonneck, A. Bohm, A. Gruze, P. Samorapoompichit, P. W. Manley, D. Fabbro, et al.
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects
Blood,
January 15, 2006;
107(2):
752 - 759.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Arora and E. M. Scholar
Role of Tyrosine Kinase Inhibitors in Cancer Therapy
J. Pharmacol. Exp. Ther.,
December 1, 2005;
315(3):
971 - 979.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi, S. V. Rajkumar, and A. A. Adjei
Introduction to a Cancer Symposium for the Practitioner
Mayo Clin. Proc.,
August 1, 2005;
80(8):
1085 - 1086.
[PDF]
|
|
|
|
|
|
|
A. Tefferi, C. A. Hanson, and D. J. Inwards
How to Interpret and Pursue an Abnormal Complete Blood Cell Count in Adults
Mayo Clin. Proc.,
July 1, 2005;
80(7):
923 - 936.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. Wirth
A role for RTKs in Hodgkin lymphoma
Blood,
May 15, 2005;
105(10):
3766 - 3766.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Chen and W. Plunkett
Sequential Blockade of Oncogenic Kinases
Am. Assoc. Cancer Res. Educ. Book,
April 1, 2005;
2005(1):
344 - 348.
[Full Text]
[PDF]
|
|
|
|
|
